Pulmonary Disease in Monroe, LA
11 verified pulmonary disease doctors in Monroe.
Pulmonologists diagnose and treat diseases of the lungs and respiratory system, such as asthma, COPD, and sleep apnea.
NPPES tenure ≠ clinical experience. "Years on NPPES" is time since the physician first registered a National Provider Identifier, not time practicing medicine. Verify current license status with the state medical board.
Verify a license at the Louisiana State Board of Medical Examiners
Dr. Marshall Irby, MD
Pulmonary Disease
CMS Open Payments· $512.53 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$512.53
Total received
27
Transactions
7
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 73th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Marshall Irby do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Otto Villa, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Robert Sarama, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Antti Maran, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Charles Gbadouwey, MD
Pulmonary Disease
CMS Open Payments· $4,394 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$4,394
Total received
100
Transactions
18
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total is higher than 91% of that group — among the highest recipients.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Charles Gbadouwey do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Ronald Hammett, MD
Pulmonary Disease
CMS Open Payments· $1,125 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$1,125
Total received
52
Transactions
10
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 81th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Ronald Hammett do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Thomas Gullatt, MD
Pulmonary Disease
CMS Open Payments· $113.21 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$113.21
Total received
2
Transactions
2
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 59th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Thomas Gullatt do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Richard Fincher, MD
Pulmonary Disease
CMS Open Payments· No payments in 2023
Industry Payments
No industry payments on record in the 2023 CMS Open Payments data. This doctor received no reported payments from drug or device makers that year.
Dr. Allyn Resch, MD
Pulmonary Disease
CMS Open Payments· $67.57 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$67.57
Total received
4
Transactions
3
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 55th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Allyn Resch do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Matthew Raley, MD
Pulmonary Disease
CMS Open Payments· $560.89 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$560.89
Total received
14
Transactions
5
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 74th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Matthew Raley do not imply any wrongdoing. Many are meals, education, or research support.
Dr. Bruno Zavala, MD
Pulmonary Disease
CMS Open Payments· $40.08 (2023)
Industry Payments (2023)
Reported by drug and device makers to CMS Open Payments. These payments are legal and disclosed — shown as context, not a judgment.
$40.08
Total received
2
Transactions
2
Paying companies
Top paying companies
Among the 13,317 pulmonary disease doctors we've analyzed, about 54% received any industry payment (median $474 among those who did). This doctor's total ranks around the 52th percentile of that group.
Benchmark reflects doctors we've analyzed, not all US pulmonary disease doctors.
Payments to Bruno Zavala do not imply any wrongdoing. Many are meals, education, or research support.